Hologic announced first quarter fiscal 2025 results, with total revenue of $1.022 billion, an increase of 1% on a constant currency basis, meeting its guidance. Non-GAAP earnings per share were $1.03, up 5%, reaching the high end of the guidance range.
The Diagnostics business performed strongly, with revenue growing 5.2% (9.1% organically excluding COVID-19), driven by double-digit growth in molecular diagnostics, Biotheranostics, and BV/CV/TV assays. However, Breast Health revenue declined 2.1% (5.8% organically), primarily due to lower capital equipment sales.
Following these results, Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products. The company now anticipates a softer year for gantry placements as customers lengthen replacement cycles, impacting the overall revenue outlook.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.